- About us
- Hospitals and centres
- Patients and visitors
- Join our team
- Get involved
- Clinician resources
- Refer your patient
New data could help to provide access to emerging treatments for Australians with slow growing but incurable blood cancers.
Princess Alexandra Hospital’s (PAH) and The University of Queensland Diamantina Institute’s Professor Maher Gandhi said there was currently no good-quality data for indolent lymphomas making it difficult for these treatments to receive government subsidy.
“A series of recent submissions for new anti-lymphoma treatments to be included on the Pharmaceutical Benefits Scheme (PBS) have been rejected due to the poor quality of health economic data available,” Prof Gandhi said.
“The less evidence there is the more likely the decision will come down against including a new treatment where the cost-per-life year is high.”
Prof Gandhi said he hoped his work would enable access to therapy for people with indolent lymphoma.
“This real world data will assist the Pharmaceutical Benefits Advisory Committee in evaluating new targeted therapies for reimbursement."
Prof Gandhi’s project has been funded by the Gilead 2017 Fellowship Research Grants Program.
The Fellowships support the development, exploration and implementation of best practice in enhancing patient care in haematological cancers, chronic viral hepatitis and HIV.
Prof Gandhi’s work was one of seven projects selected from 43 applications, the largest field since the program began in 2012.